Thank you, Mr. Chair. I'll try to make this one question count.
I'd also like to first thank the witnesses for joining us for a very interesting discussion today.
My question is for Mr. Desai.
You mentioned some of the programs that the U.S. has for procurement, and you mentioned DARPA specifically. There is a local biotech company called AbCellera that won a competition that DARPA had where companies could compete to show how they could respond to the threat of a pandemic in developing a therapy.
It just so happens that, once the pandemic hit this year, there was a significant amount of investment from the Canadian government into AbCellera to develop a treatment for COVID, which eventually they did, and it was approved by PHAC, and we've now procured 26,000 doses of the therapy.
This is an interesting example, and I was wondering if you could speak to what lessons you think we can learn from the response to the pandemic with respect to the medical sector and how this can translate to support of the tech sector, particularly to navigate the valley of death?